The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
we are actively doing a large trial that we have called prevent e4 to partially address this question if we took younger apoe4 carriers before they have dementia or before they have clinical symptoms can we show any effect on the brain and we had this immensely challenging question of should we look at 30 to 40 year olds or should we look at 55 to 70 year olds and in 2017 we made the decision to look at the 55 to 70 year olds because those people do cognitively decline with time
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
the study will possibly wrap up in 2023 and get published between 2024-2025 so that's an ongoing effort where we're giving 2 grams high-dose dha based on pilot study that we have done before showing that you need higher doses of dha to get into the brain in apoe4 carriers who do not have cognitive disease yet they may have mild disease but definitely not dementia